Evidence map›Paper›PMID 25197279›Full record

ReviewInternational journal of cell biology2014

Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases.

Moses O Oyewumi, Adnan Alazizi, Daniel Wehrung, Rami Manochakian, Fayez F Safadi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of cell biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Overview of CaExploration of targeted anti-tumor therapy · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Significance of Trask protein interactions in brain metastatic cohorts of lung cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  9. Metastatic tumors to the jaws and mouth.Head and neck pathology · 2014
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Moses O OyewumiDepartment of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Adnan AlaziziDepartment of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA.ORCID 0000-0002-7599-8114
Daniel WehrungDepartment of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA.ORCID 0000-0002-3150-678X
Rami ManochakianDivision of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Louis Stokes Veteran Affairs Medical Center, Cleveland, OH 44106, USA.ORCID 0000-0001-9142-4113
Fayez F SafadiDepartment of Anatomy and Neurobiology, College of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Northeast Ohio Medical University · USLouis Stokes Cleveland VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the second most common cancer and the leading cause of cancer related mortality in both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. It is widely accepted that tumor metastasis is a formidable barrier to effective treatment of lung cancer. The bone is one of the frequent metastatic sites for lung cancer occurring in a large number of patients. Bone metastases can cause a wide range of symptoms that could impair quality of life of lung cancer patients and shorten their survival. We strongly believe that molecular targets (tumor-related and bone microenvironment based) that have been implicated in lung cancer bone metastases hold great promise in lung cancer therapeutics. Thus, this paper discusses some of the emerging molecular targets that have provided insights into the cascade of metastases in lung cancer with the focus on bone invasion. It is anticipated that the information gathered might be useful in future efforts of optimizing lung cancer treatment strategies.

Identifiers

PMID25197279
PMCPMC4147348
OpenAlexW2145337059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.